The present application is related to and claims from U.S. patent application Ser. No. 10/687,289, filed Oct. 15, 2003, published as U.S. Published Patent Application No. US2004/0138517 (A1), Osorio et al, Multi-Modal Operation of a Medical Device System; U.S. Provisional Patent Application No. 60/503,998, filed Sep. 19, 2003; and U.S. Provisional Patent Application No. 60/418,553, filed Oct. 15, 2002.
The present invention relates to devices and methods for the detection and the treatment of nervous system disorders.
Nervous system disorders, including neurological, disorders, affect millions of people, causing death and a degradation of life. Nervous system disorders include disorders of the central nervous system, peripheral nervous system, and mental health and psychiatric disorders. Such disorders include, for example without limitation, epilepsy, Parkinson's disease, essential tremor, dystonia, and multiple sclerosis (MS). Additionally, nervous system disorders include mental health disorders and psychiatric disorders which also affect millions of individuals and include, but are not limited to, anxiety (such as general anxiety disorder, panic disorder, phobias, post traumatic stress disorder (PTSD), and obsessive compulsive disorder (OCD)), mood disorders (such as major depression, bipolar depression, and dysthymic disorder), sleep disorders (narcolepsy), obesity, and anorexia. As an example, epilepsy is the most prevalent serious neurological disease across all ages. Epilepsy is a group of neurological conditions in which a person has or is predisposed to recurrent seizures. A seizure is a clinical manifestation resulting from excessive, hypersynchronous, abnormal electrical or neuronal activity in the brain. (A neurological event is an activity that is indicative of a nervous system disorder. A seizure is a type of a neurological event.) This electrical excitability of the brain may be likened to an intermittent electrical overload that manifests with sudden, recurrent, and transient changes of mental function, sensations, perceptions, and/or involuntary body movement. Because the seizures are unpredictable, epilepsy affects a person's employability, psychosocial life, and ability to operate vehicles or power equipment. It is a disorder that occurs in all age groups, socioeconomic classes, cultures, and countries. In developed countries, the age-adjusted incidence of recurrent unprovoked seizures ranges from 24/100,000 to 53/100,000 person-years and may be even higher in developing countries. In developed countries, age specific incidence is highest during the first few months of life and again after age 70. The age-adjusted prevalence of epilepsy is 5 to 8 per 1,000 (0.5% to 0.8%) in countries where statistics are available. In the United States alone, epilepsy and seizures affect 2.3 million Americans, with approximately 181,000 new cases occurring each year. It is estimated that 10% of Americans will experience a seizure in their lifetimes, and 3% will develop epilepsy by age 75.
There are various approaches in treating nervous system disorders. Treatment therapies can include any number of possible modalities alone or in combination including, for example, electrical stimulation, magnetic stimulation, drug infusion, and/or brain temperature control.
Several devices have been disclosed for the treatment of a neurological disorder. Examples of such devices include U.S. Pat. No. 5,832,932, Elsberry, Method of Treating Movement Disorders By Brain Infusion, which discloses techniques and apparatus for infusing drugs into the brain to treat movement disorders resulting in abnormal motor behavior. An implantable pump and a catheter, the catheter having a proximal end coupled to the pump and a discharge portion for placement adjacent a predetermined infusion site in the brain for infusing therapeutic dosages of the one or more drugs into the brain. The pump is operated to discharge a predetermined dosage of the one or more drugs through the discharge portion of the catheter into the infusion site. A sensor may be used in combination with the implantable pump and catheter, whereby the sensor generates a signal relating to the extent of the abnormal motor behavior. The therapeutic dosage is regulated so that the dosage is adjusted in response to an increase in the abnormal behavior to decrease the abnormal motor behavior.
U.S. Pat. No. 6,591,138, Fischell, Low Frequency Neurostimulator For the Treatment of Neurological Disorders, discloses a system for treating neurological conditions by low frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hertz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.
U.S. Pat. No. 6,609,030, Rezai, Method of Treating Psychiatric Diseases By Neruomodulation Within the Dorsomedial Thalamus, discloses a method for treating psychiatric diseases such as Affective Disorder (including Major Depression and Bipolar Disorder), Anxiety Disorder (including General Anxiety Disorder, Obsessive Compulsive Disorder and Panic Disorder) by stimulation (either electrical and/or chemical) of the thalamus, and in particular a region within the dorsomedial nucleus of the thalamus. The method includes the steps of determining a common group of patients, each suffering from a common specific diagnosis or a psychological disorder; determining which common region of the patients' thalami are involved in carrying the pathological electrical signals and/or metabolic activity which may otherwise be generated in dissimilar and disparate regions of the brains of the patients; surgically implanting an electrode and/or catheter and electrical signal generating device and/or drug pump such that the electrode and/or catheter is positioned within the region of the thalamus identified as the dorsomedial nucleus; and selectively adjusting the level of electrical and/or chemical stimulation in accordance with the specific effect of the stimulation of the patient. In particular, the region of the thalamus most frequently associated with the aforementioned psychiatric disease is the dorsomedial nucleus.
U.S. Published Patent Application No. 2004/0002635, Hargrove, Method and Apparatus For Utilizing Amplitude-Modulated Pulse-Width Modulation Signals For Neurostimulation and Treatment of Neurological Disorders Using Electrical Stimulation, discloses a computing device-controlled system is described for the generation of amplitude-modulated pulse-width modulation (AMPWM) signals for use in treating neurological dysfunction via cranial neurostimulation, where the AMPWM signal is specifically designed to minimize the electrical impedance of the tissues of the head. A low-frequency carrier signal is determined for the AMPWM signal by measuring EEG activity at a reference site or sites, generally corresponding with the location of suspected brain dysfunction. Carrier signal frequency is variably related to critical frequency components of the EEG power spectral density, determined from statistical analysis of amplitudes and variability, and dynamically changed as a function of time to prevent entertainment. The AMPWM signal is presented to a subject via a plurality of neurostimulation delivery modes for therapeutic use.
Devices and methods have also been developed to sense a condition and then respond with a treatment for a certain neurological disorder. For example, U.S. Pat. No. 6,647,296, Fischell et al, Implantable Apparatus For Treating Neurological Disorders, discloses a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's scalp, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.
Examples in the cardiac field include U.S. Pat. No. 6,731,984, Cho et al, Method For Providing A Therapy To a Patient Involving Modifying the Therapy After Detecting an Onset of Sleep in the Patient and Implantable Medical Device Embodying Same; U.S. Pat. No. 5,284,491, Sutton et al, Cardiac Pacemaker With Hysteresis Behavior; and U.S. Pat. No. 5,193,535, Bardy et al, Method and Apparatus For Discrimination of Ventricular Tachycardia From Ventricular Fibrillation and For Treatment Thereof.
Cho et al '984 discloses an implantable medical device system is described including an implantable medical device for implantation in a patient. One embodiment of the implantable medical device includes a therapy component for providing a therapy to the patient, a minute ventilation (MV) sensing circuit producing MV values indicative of a MV of the patient at time intervals, and computational circuitry. The computational circuitry receives a number of the MV values over a period of time, calculates a statistical parameter (e.g., a mean) of the MV values, and calculates a deviation of the MV values from the statistical parameter (e.g., a standard deviation of the MV values). The computational circuitry detects an onset of sleep in the patient when the deviation of the MV values from the statistical parameter is less than a predetermined MV threshold value, and signals the therapy component to modify the therapy when the onset of sleep is detected in the patient. A method is disclosed for providing therapy to a patient, including detecting an onset of sleep in the patient, and modifying the therapy following the detecting the onset of sleep in the patient.
Sutton et al '491 discloses a pacemaker having a hysteresis feature which permits intrinsic heart activity, controlled by the sinus node to resume optimally after pacing. The pacemaker has a programmable lower rate and upper rate, a programmable lower hysteresis rate (LRH) corresponding to a lower rate hysteresis interval (LRHI), and a programmable rate (IR) intermediate an upper pacing rate (UR) and a lower pacing rate (LR). A microprocessor measures the average rate of change MAVG in the intervals between consecutive ventricular depolarizations, and compares the last intrinsic escape interval RRN to the lower rate hysteresis interval (LRHI). If the last intrinsic escape interval RRN is longer than the lower rate hysteresis interval (LRHI), and if the value of MAVG is greater than a first preselected value SLI but less than a second preselected value SL2, the pacemaker stimulates at the lower rate hysteresis (LRH) and thereafter gradually increases the pacing rate up to the intermediate rate (IR). A time counter maintains a continuous pacing at the intermediate rate (IR) for a predefined period of time, and the pacing rate is gradually decreased toward the lower pacing rate (LR).
Bardy et al '535 discloses an implantable cardioverter/defibrillator provided with method and apparatus for discrimination between ventricular tachycardia and ventricular fibrillation. The device is provided with two pairs of electrodes, each pair of electrodes coupled to processing circuitry for identifying a predetermined fiducal point in the electrical signal associated with a ventricular depolarization. The cumulative beat to beat variability of the intervals separating the two identified fiducal points, over a series of detected depolarizations is analyzed. The result of this analysis is used to distinguish between ventricular tachycardia and ventricular fibrillation.
Devices and methods have also been developed that provide multiple treatments for a single disorder. An example is U.S. Pat. No. 6,094,598, Elsberry, Method of Treating Movement Disorders By Brain Stimulation and Drug Infusion, which discloses techniques using one or more drugs and electrical stimulation for treating neural disorders, including movement disorders resulting in abnormal motor response, by means of an implantable signal generator and electrode and an implantable pump and catheter. A sensor is used to detect activity resulting from the neural disorder. A microprocessor algorithm analyzes the output from the sensor in order to regulate the stimulation and drug dosage delivered to the neural tissue.
Also, U.S. Pat. No. 5,713,923, Ward et al, Techniques For Treating Epilepsy By Brain Stimulation and Drug Infusion, U.S. Pat. No. 5,578,702, Ward et al, Techniques For Treating Epilepsy By Brain Stimulation and Drug Infusion, disclose techniques using one or more drugs and electrical stimulation for treating a neurological disorder, including epilepsy, by means of an implantable signal generator and electrode and an implantable pump and catheter. A sensor is used to detect a seizure or symptoms resulting from the onset of a seizure. A microprocessor algorithm analyzes the output from the sensor in order to regulate the stimulation and drug dosage delivered to the neural tissue.
U.S. Pat. No. 6,176,242, Rise, Method of Treating Manic Depression By Brain Infusion, discloses techniques using one or more drugs, electrical stimulation or both to treat depression or manic depression by means of an implantable signal generator and electrode and/or an implantable pump and catheter. A catheter is surgically implanted in selected sites in the brain to infuse the drugs, and one or more electrodes are surgically implanted in the brain at selected sites to provide electrical stimulation.
U.S. Published Patent Application No. US2004/0138517 (A1), Osorio et al, Multi-Modal Operation of a Medical Device System, discloses multi-modal operation for the treatment of a nervous system disorder. The medical device system supports both a first feature and a second feature associated with treatment therapy with an implanted component and an external component and may support a plurality of features during a treatment interval.
Singular among the devices and methods noted above is that all involve the treatment of a single disorder, even though multiple treatments may be applied to that single disorder. Such devices and methods then are ill-equipped and not configured to effectively treat or respond to multiple disorders within a single patient.
Many neurological disorders are co-morbidities. For example, sufferers of migraine headache are often also diagnosed with clinical depression. Likewise, epilepsy patients have a high occurrence of clinical depression as well as severe headache. Implantable medical devices have long been considered for the treatment of neurological disorders. However, these implantable medical devices are designed to treat a single disorder, often leaving the concurrent disorder untreated or, perhaps, left to rely on unrelated medication. Embodiments of the present invention provide an implantable medical device capable of concurrently treating two or more neurological disorders.
In an embodiment, the present invention provides an implantable medical device adapted to be implanted in a patient having a plurality of neurological disorders. A first therapy module is adapted to provide a first output to the patient for the treatment of a first one of the plurality of disorders. A second therapy module is adapted to provide a second output to the patient for the treatment of a second one of the plurality of disorders.
In an embodiment, at least one of the first therapy module and the second therapy module is operative in a closed loop.
In an embodiment, the at least one of the first output and the second output is a function of another of the first output and the second output.
In an embodiment, a sensor is adapted to detect a sensed event from the patient associated with at least one of the plurality of neurological disorders and at least one of the first therapy module and the second therapy module is operatively coupled to the sensor and being responsive to a sensed event from the patient.
In an embodiment, the first therapy module is a drug delivery module and wherein the first output is the delivery of a medicament.
In an embodiment, the second therapy module is an electrical stimulator module and wherein the second output is an electrical stimulus signal.
In an embodiment, at least one of the drug delivery module and the electrical stimulator module is operative in a closed loop responsive to the other of the drug delivery module and the electrical stimulator module.
In an embodiment, a sensor is adapted to detect a sensed event from the patient, and at least one of the drug pump module and the electrical stimulator module is operatively coupled to the sensor and responsive to a sensed event from the patient.
In an embodiment, the present invention provides a method for the treatment of a plurality of neurological disorders in a patient using an implantable medical device having a first therapy module and a second therapy module. A first output from the first therapy module is provided to the patient for the treatment of a first one of the plurality of neurological disorders. A second output from the second therapy module is provided to the patient for the treatment of a second one of the plurality of neurological disorders.
In an embodiment, at least one of the first therapy module and the second therapy module is operated in a closed loop.
In an embodiment, the at least one of the first output and the second output being a function of another of the first output and the second output.
In an embodiment, a sensed event is detected from the patient associated with at least one of the plurality of neurological disorders and operating at least one of the first therapy module and the second therapy module responsive to the sensed event.
In an embodiment, the first therapy module is a drug delivery module and wherein the first output is the delivery of a medicament.
In an embodiment, the second therapy module is an electrical stimulator module and the second output is an electrical stimulus signal.
In an embodiment, at least one of the drug delivery module and the electrical stimulator module is operated in a closed loop being responsive to the other of the drug delivery module and the electrical stimulator module.
In an embodiment, a sensed event is detected from the patient and wherein at least one of the drug pump module and the electrical stimulator module is responsive to the sensed event.
In an embodiment, the implantable medical device is implanted in the patient.
The entire content of U.S. Published Patent Application No. US2004/0138517 (A1), Osorio et al, Multi-Modal Operation of a Medical Device System, is hereby incorporated by reference. In aspects of the present invention, the multi-modal operation of the medical device system disclosed in Osorio et al '517 would be applied to the treatment of multiple neurological disorders.
Medical device 10 may deliver two different treatment therapies to two different electrodes (16a and 16b) placed in differing neurological locations for the treatment of multiple neurological disorders.
Treatment therapy for an individual neurological disorder is conventional and may not significantly differ from the treatment provided by a medical driving only one active electrode and having only one treatment modality. That is, known treatment therapies for a single neurological disorder, e.g., epilepsy, may be employed as one treatment therapy applied to one of the electrodes, e.g., electrode 16a, of medical device 10 for a first neurological disorder. Similarly, a different, but still known, treatment therapy may be concurrently employed as a second treatment therapy applied to another of the electrodes, e.g., electrode 16b, of medical device 10 for a second neurological disorder. In the medical device illustrated in
Alternatively, implantable medical device 10 may be implanted under the scalp or in the cranium as illustrated in
Leads 14, 14a and 14b are operatively coupled to medical device 10 and may be routed through the neck, just under the skin to the skull. The distal end of each lead (14 or 14a and 14b) may be inserted through a cranial burr hole and into a specific target of the brain of interest for treatment of a particular neurological disorder. The distal end of leads 14 or 14a and 14b terminate in electrodes 16a and 16b, or alternatively, any combination of output ports and/or thermal transducers. In this of multiple treatment for epilepsy and depression, the distal end of one electrode, e.g., electrode 16a, may be located in a region of the brain that when therapy is applied reduces seizures and the distal end of another electrode, e.g., electrode 16b, may be located in a region of the brain that when therapy is applied symptoms of depression are reduced.
Leads 14, electrodes 16 and/or other wires may be employed for use as therapy outputs of medical device 10, e.g., at least one pair of electrodes, a catheter output port and/or a thermal transducer. Leads 14, electrodes 16 and/or other wires may also be employed for sensing functions, e.g., an electrode 16 may be employed for sensing electrical activity of the brain. Leads 14, electrodes 16 and/or other wires may also be employed as an extension to another lead 14, electrode 16 and/or other wire. Leads 14, electrodes 16 and/or other wires may also be employed to furcate other leads 14, electrodes 16 and/or other wires to access multiple targets.
This is illustrated in
It is also possible that cross feedback may be employed between therapy modules. For example, if it is known that a first therapy, e.g., a drug infusion therapy, may be adversely impacted by a second therapy, e.g., an electrical stimulation pulse, then either the first or second therapy may be suspended for a time or for an event during the known activity of the other therapy. This is possible without relying on the sensed activity of the other therapy, through sensor 30, but may be achieved either in control 20, by direction connection between first therapy module 22 and second therapy module 26 or by direct feedback from either first therapy module 22 or second therapy module 26, or both.
Medical device 10 illustrated in
While medical device 10 has been illustrated and described with respect to
Medical device 10 can deliver therapy in open-loop, e.g., periodic, mode, in closed-loop, e.g., responsive to a neurological event, or a combination of open-loop and closed-loop modes. In the case of epilepsy and depression, closed-loop electrical stimulation may be delivered responsive to an ictal event while periodic stimulation or drug infusion may be delivered to reduce the symptoms of depression.
The flow chart of
The process begins (710) and a cyclical stimulation (712) of target number 2, i.e., second therapy output 28. A determination (714) is made to see if the second therapy output is activated. If the second therapy output is deactivated, the process jumps to processing step 724. However, if second therapy output is activated, a determination (716) is made to see if blanking mode is enabled. If blanking is enabled, electrode inputs 36 to signal processing and detection circuit 38 are switched off, i.e., blanked, (718) during open-loop stimulation and, hence, event detection is disabled during the time of the actual active stimulation signal and the process jumps to processing step 724. Alternatively, a determination (720) is made to see if filtering mode is enabled. If filtering mode is enabled, the signal processing and detection circuit 38 continues to operate for event detection but the sensed signals from sensing circuitry 36 are filtered (722) for the open-loop second therapy output. This can be accomplished since it can be known the content, parameters and timing of the open-loop second therapy output. The specific open-loop second therapy signal is removed and the filtered signal is processed (724) through an event detection algorithm. Optionally, processing step 724 may only process the sensed signal if no or only a minimal open-loop second therapy output is present in the sensed signal, whether blanked and/or filtered or not. Either of these three techniques, or any combination or all of them, may be utilized to help ensure that the open-loop second therapy output signal does not materially affect the event detection algorithm. If desirable, any of these three modes of operation are selectable using external programmer 18.
If an event is detected (726), then the closed-loop first therapy output is initiated (728). If an event is not detected (726), then the process returns to determine (712) if the open-loop second therapy output is activated.
It may be desirable in certain circumstances that one of the therapies be a function of another therapy event. For example, if an ictal event is detected and a drug infusion therapy output is initiated, it may, in some circumstances, be desirable to temporarily suspend another therapy, e.g., open loop electrical stimulation for depression. Another reason for suspending electrical stimulation therapy, for example, might be because the electrical stimulation might adversely affect a drug being infused and/or the infusion process. In this case, electrical stimulation might be suspended for a predetermined period of time.
Thus, embodiments of invention are disclosed. One skilled in the art will appreciate that the present invention can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation, and the present invention is limited only by the claims that follow.
Number | Name | Date | Kind |
---|---|---|---|
3522811 | Schwartz et al. | Aug 1970 | A |
3850161 | Liss | Nov 1974 | A |
3863625 | Viglione et al. | Feb 1975 | A |
3967616 | Ross | Jul 1976 | A |
3993046 | Fernandez et al. | Nov 1976 | A |
4019518 | Maurer et al. | Apr 1977 | A |
4038536 | Feintuch | Jul 1977 | A |
4295474 | Fischell | Oct 1981 | A |
4373527 | Fischell | Feb 1983 | A |
4417592 | John | Nov 1983 | A |
4566464 | Piccone et al. | Jan 1986 | A |
4581758 | Coker et al. | Apr 1986 | A |
4610259 | Cohen et al. | Sep 1986 | A |
4692147 | Duggan | Sep 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4944299 | Sulvain | Jul 1990 | A |
5113869 | Napholz | May 1992 | A |
5193535 | Bardy et al. | Mar 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5284491 | Sutton et al. | Feb 1994 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5311869 | Okazaki | May 1994 | A |
5311876 | Olsen et al. | May 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5360437 | Thompson | Nov 1994 | A |
5487754 | Snell et al. | Jan 1996 | A |
5626145 | Clapp et al. | May 1997 | A |
5626630 | Markowitz et al. | May 1997 | A |
5683422 | Rise | Nov 1997 | A |
5713922 | King | Feb 1998 | A |
5713923 | Ward et al. | Feb 1998 | A |
5716377 | Rise et al. | Feb 1998 | A |
5720770 | Nappholz et al. | Feb 1998 | A |
5743860 | Hively et al. | Apr 1998 | A |
5752976 | Duffin | May 1998 | A |
5792186 | Rise | Aug 1998 | A |
5832932 | Elsberry et al. | Nov 1998 | A |
5938689 | Fischell et al. | Aug 1999 | A |
5978702 | Ward et al. | Nov 1999 | A |
5995868 | Dorfmeister et al. | Nov 1999 | A |
6006124 | Fischell et al. | Dec 1999 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6018682 | Rise | Jan 2000 | A |
6061593 | Fischell et al. | May 2000 | A |
6066163 | John | May 2000 | A |
6083248 | Thompson | Jul 2000 | A |
6094598 | Elsberry et al. | Jul 2000 | A |
6117066 | Abrams et al. | Sep 2000 | A |
6128537 | Rise | Oct 2000 | A |
6128538 | Fischell et al. | Oct 2000 | A |
6134474 | Fischell et al. | Oct 2000 | A |
6161045 | Fischell et al. | Dec 2000 | A |
6169387 | Kalb | Jan 2001 | B1 |
6176242 | Rise | Jan 2001 | B1 |
6185452 | Schulman et al. | Feb 2001 | B1 |
6200265 | Walsh et al. | Mar 2001 | B1 |
6205359 | Bojeva | Mar 2001 | B1 |
6208894 | Schulman et al. | Mar 2001 | B1 |
6224549 | Drongelen | May 2001 | B1 |
6227203 | Rise et al. | May 2001 | B1 |
6230049 | Fischell et al. | May 2001 | B1 |
6269270 | Bojeva | Jul 2001 | B1 |
6337997 | Rise | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6353754 | Fischell et al. | Mar 2002 | B1 |
6354299 | Fischell et al. | Mar 2002 | B1 |
6356784 | Lozano et al. | Mar 2002 | B1 |
6360122 | Fischell et al. | Mar 2002 | B1 |
6366813 | Di Lorenzo | Apr 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6427086 | Fischell et al. | Jul 2002 | B1 |
6459936 | Fischell et al. | Oct 2002 | B2 |
6466822 | Pless | Oct 2002 | B1 |
6473639 | Fischell et al. | Oct 2002 | B1 |
6480743 | Kirkpatrick et al. | Nov 2002 | B1 |
6529774 | Greene | Mar 2003 | B1 |
6560486 | Osorio et al. | May 2003 | B1 |
6591138 | Fischell et al. | Jul 2003 | B1 |
6597953 | Boling | Jul 2003 | B2 |
6597954 | Pless et al. | Jul 2003 | B1 |
6606521 | Paspa et al. | Aug 2003 | B2 |
6609030 | Rezai et al. | Aug 2003 | B1 |
6618623 | Pless et al. | Sep 2003 | B1 |
6647296 | Fischell et al. | Nov 2003 | B2 |
6731984 | Cho et al. | May 2004 | B2 |
6735479 | Fabian et al. | May 2004 | B2 |
6782292 | Whitehurst | Aug 2004 | B2 |
20010051819 | Fischell et al. | Dec 2001 | A1 |
20010056290 | Fischell et al. | Dec 2001 | A1 |
20020002390 | Fischell et al. | Jan 2002 | A1 |
20020013614 | Thompson | Jan 2002 | A1 |
20020049482 | Fabian et al. | Apr 2002 | A1 |
20020072770 | Pless | Jun 2002 | A1 |
20020077670 | Archer et al. | Jun 2002 | A1 |
20020099412 | Fischell et al. | Jul 2002 | A1 |
20020116042 | Boling | Aug 2002 | A1 |
20020169485 | Pless et al. | Nov 2002 | A1 |
20030004428 | Pless et al. | Jan 2003 | A1 |
20030028072 | Fischell et al. | Feb 2003 | A1 |
20030073917 | Echauz et al. | Apr 2003 | A1 |
20030074033 | Pless et al. | Apr 2003 | A1 |
20030144711 | Pless et al. | Jul 2003 | A1 |
20030149457 | Tcheng et al. | Aug 2003 | A1 |
20030176807 | Goetz et al. | Sep 2003 | A1 |
20030195602 | Boling | Oct 2003 | A1 |
20040002635 | Hargrove et al. | Jan 2004 | A1 |
20040068195 | Massicotte et al. | Apr 2004 | A1 |
20040127942 | Yomtov et al. | Jul 2004 | A1 |
20040133248 | Frei et al. | Jul 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20050070969 | Gerber | Mar 2005 | A1 |
20050119712 | Shafer | Jun 2005 | A1 |
Number | Date | Country |
---|---|---|
0 911 061 | Apr 1999 | EP |
0 911 061 | Nov 1999 | EP |
1 145 735 | Oct 2001 | EP |
1 145 736 | Oct 2001 | EP |
0 904 119 | Jan 2004 | EP |
1 145 735 | Apr 2004 | EP |
1 145 736 | Apr 2004 | EP |
WO 9742990 | Nov 1997 | WO |
WO 0197906 | Dec 2001 | WO |
WO 2004062470 | Jul 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20070255323 A1 | Nov 2007 | US |